BT44

Research use only, not for human use.

BT44 is a novel, second-generation glial cell linederived neurotropic factor mimetic with improved biological activity and is a lead compound for the treatment of neurodegenerative disorders.

BT44 is a selective RET activator. BT44 can penetrate through the blood-brain barrier and can be used for the research of neurodegenerative disorders and diabetes mellitus.

Western Blot Analysis Cell Line:GFRα3-transfected MG87RET cells Concentration:7.5, 18, 35 and 75 μM Incubation Time:15 min Result:Increased RET and ERK phosphorylation.

Animal Model:Wistar rats, spinal nerve ligation (SNL) and Streptozotocin (STZ; HY-13753)-induced diabetes mellitus models Dosage:5, 12.5 or 25 mg/kg Administration:Subcutaneous injecton, every second day for 10, 42 or 14 days Result:Alleviated mechanical allodynia in the SNL animals. Treatment with the dose of 5 mg/kg alleviated mechanical hyperalgesia in the STZ-treated animals, while the 12.5 mg/kg dose was not effective. Concentration of 5 mg/kg attenuated cold allodynia in the STZ-treated animals during the first two weeks while the effect of 12.5 mg/kg was not significant. Animal Model:Wistar rats, SNL-induced diabetes mellitus model Dosage:12.5 or 25 mg/kg Administration:Subcutaneous injecton, every second day for 10 days Result:Led to a significant increase in the number of IB4 expressing neurons in the ipsilateral DRGs. The 12.5 mg/kg dose protected IB4-positive neurons from SNL-induced lesion.

——

Others

Other Targets

Others

——

——

924759-42-2

577.59

C28H27F4N3O4S

>98% (HPLC)

In Vitro:?DMSO : 62.5 mg/mL (108.21 mM; Ultrasonic (<60°C)

O(C)C1=C(C=C(S(=O)(=O)N2CC=3C(CC2)=CC=CC3)C=C1)N4CCN(C(=O)C5=C(C(F)(F)F)C=C(F)C=C5)CC4

——

(-20℃)

With Ice Pack

≥ 2 years